The MDC business produces components for medical device manufacturers globally with a focus on precious metal alloys and nitinol
To accelerate the development of next-generation radioconjugates to treat cancer
Lonza plans to invest approximately CHF 500 million to upgrade the facility
The plan essentially was to separate Aster’s India and GCC businesses to unlock long-term value
Additional capacity broadens Grace’s fine chemical capabilities for API production
Ukrainian marketing approvals for paclitaxel, oxaliplatin and irinotecan mark a significant milestone in the company’s global expansion strategy
Versavo is the first Dr. Reddy's biosimilar product to be approved and launched in the UK
Christoph Funke's extensive career includes leadership roles at organizations such as Fresenius Kabi and Strides Pharma Science
Both organisations enter into a long- term collaboration to expand patient access in India
New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day
Subscribe To Our Newsletter & Stay Updated
